TINUBU-SQUARE
21.1.2021 13:02:12 CET | Business Wire | Press release
Tinubu Square, the market leader for enterprise software solutions to Credit and Surety Insurers, announces cooperation with Microsoft, the leading provider in Business Intelligence solutions.
Olivier Placca , Tinubu Square co-founder and Deputy CEO declares: “This cooperation is strategic for Tinubu Square to continue to offer carriers best-in-class technologies in the long run using the strength of Power BI across all business lines of our SaaS-based, end-to-end Enterprise Solution Platform. Our primary objective is answering our customers’ needs. Integrating Power BI to our Credit Insurance and Surety Platform offers them key benefits such as powerful insights, a scalable solution and settings on-the-fly. To take full advantage of our Business Intelligence capabilities, customers can tailor their own reports using a specifically designed Tinubu® CIS data model, increasing efficiency and data relevance.
Offer Sadey , Chief Technical Officer at Tinubu Square, explains: “Before choosing Microsoft, we ran through a market research with full technical assessment of the different offerings. We wanted to be sure to integrate the best solution for our customers’ benefit. It had to perfectly fit our own solutions and enhance them; we found that Microsoft Power BI was the right technology for achieving that end.
Today, Power BI is integrated in both our Trade Credit Insurance and our Surety SaaS Solutions (Tinubu® CIS & Tinubu® eSURETY®). Choosing Power BI brings the assurance of benefiting from the best technical tool. It is scalable to the customer’s business needs and is highly secured. It has a strong API enabling carriers to personalize the whole configuration of the reports they need and customize their different workspaces. Configuration is actually very easy and can be done on-the-go. Customers can also connect to the Data Warehouse for their own needs of data analysis and prediction.
Another advantage is the cost; Power BI is very affordable and allows us to continue offering high-end technological services while remaining cost-competitive.
Overall, this collaboration with Microsoft is built on a solid policy: a progressive licensing mode and a strong global support – technical, legal and business - allowing rapid scalability and therefore growth for our customers.”
Patrice Amann
, Senior Director, Financial Services Business Lead - EMEA, at Microsoft expresses: “Being at the vanguard of technological innovations, Microsoft developed Power BI which is specifically designed to facilitate businesses’ strategic decisions and growth.
Today, business forecasts and decision-making processes rely solely on the quality of data, transformed into knowledge, and their real-time availability. Every company is looking for the guaranty that their data and cloud services will be fully secured and supported at all time, whether their activities spread on a global scale or is purely local.”
He adds: “This collaboration with Tinubu Square shows that Microsoft Business Intelligence solutions are also designed to perfectly adjust to and match the need for digitalization in the Credit Insurance and Surety industry. Our goal is to provide the necessary technology to contribute to the large success of Tinubu Square’s specialized solutions for carriers, and this cooperation materializes a joint intention between both companies to answer exact business needs and provide an always optimized customer experience.”
About Tinubu Square
– www.tinubu.com
— @TinubuGroup
Tinubu Square is the industry-leading SaaS platform vendor, enabling Credit Insurance & Surety digital transformation. For 20 years, Tinubu Square has provided Credit & Surety insurers across the globe with software and services allowing them to offer best-in-class customer experience, as well as significantly reduce their exposure to risk and their financial, operational and technical costs. Tinubu Square has an international footprint with customers in over 20 countries, including 30 of the top 60 worldwide Credit & Surety underwriters.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210121005461/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom